Austgulen R
Postgrad Med J. 1985;61 Suppl 4:93-5.
Twenty children with different malignancies were vaccinated using an Oka-strain varicella vaccine (Varilrix) obtained from Smith Kline-RIT. Until now, no serious side effects to the vaccine have been observed and none of the vaccinees have had a varicella infection during this period. Nine children have been tested for cell-mediated immune responses against varicella antigen. Antibodies against varicella have been measured using an enzyme-linked immunosorbent assay technique. Tests were performed 4 weeks, 6 and 12 months after vaccination; at 4 weeks, 85% of the children had seroconverted, but by 12 months, those patients who were negative before vaccination had no detectable antibodies. While the blastogenic lymphocyte response to varicella antigen gradually increased during the first year after vaccination, it was much lower than after natural infection. The results indicate the need for revaccination, probably within 6 months after the first vaccination.
使用从史克-里特公司获得的Oka株水痘疫苗（Varilrix）对20名患有不同恶性肿瘤的儿童进行了接种。到目前为止，尚未观察到该疫苗有严重的副作用，在此期间也没有接种者感染水痘。已对9名儿童进行了针对水痘抗原的细胞介导免疫反应检测。使用酶联免疫吸附测定技术测量了针对水痘的抗体。在接种疫苗后的4周、6个月和12个月进行了检测；在4周时，85%的儿童出现了血清转化，但到12个月时，那些接种前呈阴性的患者没有可检测到的抗体。虽然接种疫苗后第一年对水痘抗原的淋巴细胞增殖反应逐渐增加，但远低于自然感染后。结果表明可能需要在首次接种后6个月内进行再次接种。
